Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.34 |
| ▸ | ACP1 | P24666 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 2/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.31 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6840149 | 0.87 | TOP2A (0.38) | TLR7PIM3KDM4EMAPT | |
| SCHEMBL6838731 | 0.85 | CYP3A4 (0.35) | TLR7TLR8MAPT | |
| SCHEMBL6837676 | 0.84 | EGFR (0.42) | TLR7TLR8EGFR | |
| SCHEMBL6837643 | 0.84 | ACP1 (0.38) | TLR7ACP1 | |
| SCHEMBL6834043 | 0.84 | ADRB2 (0.37) | ACP1DCTPP1KDM4E | |
| SCHEMBL6838715 | 0.83 | ACP1 (0.37) | TLR7ACP1 | |
| SCHEMBL6833994 | 0.82 | CYP3A4 (0.35) | MAPT | |
| Fumaric Acid SCHEMBL6838537 | 0.81 | CYP3A4 (0.33) | TLR7TLR8 | |
| Fumaric Acid SCHEMBL6838538 | 0.81 | CYP3A4 (0.33) | TLR7TLR8 | |
| SCHEMBL6837751 | 0.81 | CYP3A4 (0.37) | ACP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1256582-A1 | 1H-IMIDAZOPYRIDINE DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | IL2, IL1A, IL4 | TLR7 964/4885TLR8 999/4885ACP1 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.